Fennec Pharmaceuticals Inc. (FENC) Insider Trading Activity
NASDAQ$6.84
Market Cap
$188.77M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
576 of 877
Rank in Industry
332 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
FENC Insider Trading Activity
FENC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $469,060 | 17 | 100 |
Related Transactions
| RALLIS CHRIS A | director | 0 | $0 | 4 | $60,882 | $-60,882 |
| Raykov Rosty | CHIEF EXECUTIVE OFFICER | 0 | $0 | 13 | $408,178 | $-408,178 |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Activity of Fennec Pharmaceuticals Inc.
Over the last 12 months, insiders at Fennec Pharmaceuticals Inc. have bought $0 and sold $469,060 worth of Fennec Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Fennec Pharmaceuticals Inc. have bought $0 and sold $1.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 29,167 shares for transaction amount of $0 was made by Raykov Rosty (CHIEF EXECUTIVE OFFICER) on 2024‑04‑01.
List of Insider Buy and Sell Transactions, Fennec Pharmaceuticals Inc.
| 2025-05-05 | Sale | Raykov Rosty | director | 10,000 0.0364% | $6.31 | $63,100 | 0.00% | |
| 2025-04-04 | Sale | Raykov Rosty | director | 10,000 0.0362% | $5.25 | $52,500 | +14.29% | |
| 2025-03-05 | Sale | Raykov Rosty | director | 10,000 0.0363% | $6.79 | $67,900 | -9.19% | |
| 2025-02-14 | Sale | RALLIS CHRIS A | director | 1,186 0.0044% | $6.82 | $8,089 | -5.99% | |
| 2025-02-05 | Sale | Raykov Rosty | director | 10,000 0.0365% | $6.66 | $66,600 | -5.52% | |
| 2025-01-06 | Sale | Raykov Rosty | director | 10,000 0.0365% | $6.08 | $60,800 | +4.24% | |
| 2024-12-05 | Sale | Raykov Rosty | director | 796 0.003% | $6.04 | $4,808 | +8.65% | |
| 2024-12-03 | Sale | Raykov Rosty | director | 1,635 0.0059% | $6.13 | $10,023 | -0.32% | |
| 2024-12-02 | Sale | RALLIS CHRIS A | director | 6,409 0.0225% | $6.14 | $39,351 | -0.48% | |
| 2024-11-04 | Sale | Raykov Rosty | director | 2,431 0.0082% | $4.31 | $10,478 | +31.94% | |
| 2024-10-08 | Sale | RALLIS CHRIS A | director | 1,406 0.0045% | $4.53 | $6,369 | +34.59% | |
| 2024-10-01 | Sale | Raykov Rosty | director | 2,431 0.0085% | $4.94 | $12,009 | +25.62% | |
| 2024-09-04 | Sale | Raykov Rosty | director | 2,431 0.0088% | $5.52 | $13,419 | +7.01% | |
| 2024-08-01 | Sale | Raykov Rosty | CHIEF EXECUTIVE OFFICER | 2,431 0.0089% | $6.25 | $15,206 | -8.29% | |
| 2024-07-05 | Sale | RALLIS CHRIS A | director | 1,173 0.0043% | $6.03 | $7,073 | +2.07% | |
| 2024-07-02 | Sale | Raykov Rosty | CHIEF EXECUTIVE OFFICER | 2,431 0.0091% | $6.13 | $14,902 | -1.66% | |
| 2024-06-03 | Sale | Raykov Rosty | CHIEF EXECUTIVE OFFICER | 2,431 0.0089% | $6.76 | $16,434 | -10.55% | |
| 2024-05-01 | Sale | Raykov Rosty | CHIEF EXECUTIVE OFFICER | 2,431 0.009% | $9.11 | $22,152 | -33.28% | |
| 2024-04-22 | Sale | Haigh Adrian | CHIEF OPERATING OFFICER | 22,223 0.0814% | $9.32 | $207,029 | -35.13% | |
| 2024-04-19 | Sale | Haigh Adrian | CHIEF OPERATING OFFICER | 22,222 0.082% | $9.34 | $207,442 | -34.69% |
Total: 155
*Gray background shows transactions not older than one year
Insider Historical Profitability
3.09%
| Raykov Rosty | director | 53587 0.1942% | $366,535.08 | 1 | 22 | |
| RALLIS CHRIS A | director | 53020 0.1921% | $362,656.80 | 0 | 13 | |
| Butts Robert W | 41504000 150.3883% | $283.89M | 1 | 0 | ||
| Southpoint Capital Advisors LP | 10 percent owner | 4077214 14.7736% | $27.89M | 3 | 1 | +14.67% |
| Essetifin SPA | 10 percent owner | 3993694 14.471% | $27.32M | 2 | 0 | +12.47% |
| MANCHESTER MANAGEMENT CO LLC | 10 percent owner | 2017357 7.3098% | $13.8M | 42 | 0 | |
| MANCHESTER MANAGEMENT PR, LLC | 10 percent owner | 1250000 4.5293% | $8.55M | 37 | 16 | <0.0001% |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 104271 0.3778% | $713,213.64 | 1 | 10 | |
| Haigh Adrian | CHIEF OPERATING OFFICER | 0 0% | $0 | 0 | 6 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$7,224,762 | 91 | -8.21% | $206.22M | |
$860,541,348 | 82 | -5.10% | $194.37M | |
$613,304,943 | 46 | 11.85% | $184.67M | |
$11,468,215 | 44 | 17.78% | $180.11M | |
$17,983,739 | 41 | 102.87% | $186.94M | |
$2,545,071 | 34 | 16.59% | $204.63M | |
$41,069,367 | 23 | 54.64% | $185.66M | |
$2,747,487 | 21 | -19.10% | $182.43M | |
$46,858,891 | 18 | -11.58% | $199.26M | |
$1,345,573 | 16 | 15.45% | $219.08M | |
$1,229,070 | 10 | 23.53% | $187.45M | |
$145,296,407 | 8 | -0.98% | $182.61M | |
$94,000,000 | 7 | -20.84% | $208.76M | |
Fennec Pharmaceuticals Inc. (FENC) | $8,286,963 | 6 | 3.09% | $188.77M |
$4,845,667 | 6 | 5.11% | $191.2M | |
$55,858,393 | 5 | 14.11% | $178.49M | |
$79,238,118 | 4 | -26.47% | $214.68M | |
$149,309 | 3 | 6.07% | $176.19M | |
$9,999,990 | 1 | 32.51% | $189.99M |
FENC Institutional Investors: Active Positions
| Increased Positions | 34 | +50.75% | 2M | +15.54% |
| Decreased Positions | 25 | -37.31% | 807,046 | -5.43% |
| New Positions | 11 | New | 2M | New |
| Sold Out Positions | 11 | Sold Out | 215,603 | Sold Out |
| Total Postitions | 76 | +13.43% | 16M | +10.11% |
FENC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Southpoint Capital Advisors Lp | $25,686.00 | 14.56% | 4.08M | 0 | 0% | 2024-12-31 |
| Sonic Gp Llc | $15,166.00 | 8.6% | 2.41M | 0 | 0% | 2024-12-31 |
| Solas Capital Management, Llc | $14,181.00 | 8.04% | 2.25M | +327,383 | +17.02% | 2024-12-31 |
| Rosalind Advisors, Inc. | $7,937.00 | 4.5% | 1.26M | +1M | New | 2024-12-31 |
| Blackrock, Inc. | $7,877.00 | 4.47% | 1.25M | +23,956 | +1.95% | 2025-03-31 |
| Dg Capital Management, Llc | $7,023.00 | 3.98% | 1.11M | -407,512 | -26.77% | 2024-12-31 |
| Vanguard Group Inc | $6,109.00 | 3.46% | 969,754 | -78,137 | -7.46% | 2024-12-31 |
| Harbert Fund Advisors, Inc. | $2,941.00 | 1.67% | 466,869 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $2,182.00 | 1.24% | 346,376 | +197,914 | +133.31% | 2024-12-31 |
| State Street Corp | $2,140.00 | 1.21% | 339,713 | +11,454 | +3.49% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.